India bets ₹10,000 crore on a leap from generic drugs to biologics
Biopharma SHAKTI aims to build the research, clinical-trial and manufacturing ecosystem India needs to move from low-cost generic copies to high-value biological medicines.
Skip to content
Loading Now
Post Comment